A Phase II Trial of Pevonedistat and Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A Phase II Trial of Pevonedistat and Docetaxel in Patients with Previously Treated Advanced Non-Small Cell Lung Cancer
Authors
Keywords
-
Journal
Clinical Lung Cancer
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2023-10-26
DOI
10.1016/j.cllc.2023.10.011
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non–Small-Cell Lung Cancer Previously Treated With Immunotherapy—Lung-MAP S1800A
- (2022) Karen L. Reckamp et al. JOURNAL OF CLINICAL ONCOLOGY
- KRAS in NSCLC: State of the Art and Future Perspectives
- (2022) Priscilla Cascetta et al. Cancers
- Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
- (2016) Roy S Herbst et al. LANCET
- Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
- (2015) Julie Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer
- (2015) Hossein Borghaei et al. NEW ENGLAND JOURNAL OF MEDICINE
- Induction of p21-Dependent Senescence by an NAE Inhibitor, MLN4924, as a Mechanism of Growth Suppression
- (2015) Lijun Jia et al. NEOPLASIA
- Targeting Neddylation Pathways to Inactivate Cullin-RING Ligases for Anticancer Therapy
- (2014) Yongchao Zhao et al. ANTIOXIDANTS & REDOX SIGNALING
- Inactivation of SAG/RBX2 E3 ubiquitin ligase suppresses KrasG12D-driven lung tumorigenesis
- (2014) Hua Li et al. JOURNAL OF CLINICAL INVESTIGATION
- Overactivated Neddylation Pathway as a Therapeutic Target in Lung Cancer
- (2014) Lihui Li et al. JNCI-Journal of the National Cancer Institute
- Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial
- (2014) Edward B Garon et al. LANCET
- Cullin-RING Ligases as Attractive Anti-cancer Targets
- (2013) Yongchao Zhao et al. CURRENT PHARMACEUTICAL DESIGN
- Functional characterization of SAG/RBX2/ROC2/RNF7, an antioxidant protein and an E3 ubiquitin ligase
- (2012) Yi Sun et al. Protein & Cell
- Inhibition of NEDD8-Activating Enzyme Induces Rereplication and Apoptosis in Human Tumor Cells Consistent with Deregulating CDT1 Turnover
- (2011) M. A. Milhollen et al. CANCER RESEARCH
- NEDD8-Targeting Drug MLN4924 Elicits DNA Rereplication by Stabilizing Cdt1 in S Phase, Triggering Checkpoint Activation, Apoptosis, and Senescence in Cancer Cells
- (2010) J. J. Lin et al. CANCER RESEARCH
- Validation of SAG/RBX2/ROC2 E3 Ubiquitin Ligase as an Anticancer and Radiosensitizing Target
- (2010) L. Jia et al. CLINICAL CANCER RESEARCH
- Randomized Phase III Trial Comparing Single-Agent Paclitaxel Poliglumex (CT-2103, PPX) with Single-Agent Gemcitabine or Vinorelbine for the Treatment of PS 2 Patients with Chemotherapy-Naïve Advanced Non-small Cell Lung Cancer
- (2010) Mary E.R. O'Brien et al. Journal of Thoracic Oncology
- An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer
- (2009) Teresa A. Soucy et al. NATURE
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
- (2008) E.A. Eisenhauer et al. EUROPEAN JOURNAL OF CANCER
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now